JP2017523796A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523796A5
JP2017523796A5 JP2017506955A JP2017506955A JP2017523796A5 JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5 JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5
Authority
JP
Japan
Prior art keywords
seq
following sequence
encephalitis virus
structural protein
equine encephalitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523796A (ja
JP6824154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/003997 external-priority patent/WO2016021209A1/en
Publication of JP2017523796A publication Critical patent/JP2017523796A/ja
Publication of JP2017523796A5 publication Critical patent/JP2017523796A5/ja
Application granted granted Critical
Publication of JP6824154B2 publication Critical patent/JP6824154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506955A 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 Active JP6824154B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462035037P 2014-08-08 2014-08-08
US62/035,037 2014-08-08
US201462079128P 2014-11-13 2014-11-13
US62/079,128 2014-11-13
US201562101514P 2015-01-09 2015-01-09
US62/101,514 2015-01-09
US201562120569P 2015-02-25 2015-02-25
US62/120,569 2015-02-25
US201562198949P 2015-07-30 2015-07-30
US62/198,949 2015-07-30
PCT/JP2015/003997 WO2016021209A1 (en) 2014-08-08 2015-08-07 Virus like particle comprising modified envelope protein e3

Publications (3)

Publication Number Publication Date
JP2017523796A JP2017523796A (ja) 2017-08-24
JP2017523796A5 true JP2017523796A5 (enExample) 2018-09-06
JP6824154B2 JP6824154B2 (ja) 2021-02-03

Family

ID=55263499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506955A Active JP6824154B2 (ja) 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Country Status (6)

Country Link
US (1) US9969986B2 (enExample)
EP (1) EP3177720B1 (enExample)
JP (1) JP6824154B2 (enExample)
CN (1) CN106795513B (enExample)
TW (1) TWI720946B (enExample)
WO (1) WO2016021209A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014020052B8 (pt) 2012-02-16 2023-04-18 Vlp Therapeutics Llc Partícula do tipo vírus, composições, método de produção de anticorpo e uso da referida partícula
KR20160016856A (ko) 2013-06-03 2016-02-15 브이엘피 테라퓨틱스 엘엘씨 말라리아 백신
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
CN105792842B (zh) 2013-10-11 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 埃巴病毒疫苗
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
JP6942309B2 (ja) 2014-09-11 2021-09-29 ブイエルピー・セラピューティクス・インコーポレイテッドＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． フラビウイルスウイルス様粒子
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) * 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
IL303650B2 (en) 2016-09-02 2025-02-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
US11129886B2 (en) 2017-03-28 2021-09-28 Children's Hospital Medical Center VLP-based bivalent Ebola vaccines and methods of making and using same
CN118909082A (zh) * 2017-03-28 2024-11-08 俄亥俄州创新基金会 一种分离的肽
AU2018388071B2 (en) * 2017-12-20 2025-02-06 Vlp Therapeutics, Inc. Alphavirus replicon particle
AU2019216873B2 (en) * 2018-02-07 2025-08-14 Imugene Limited A vaccine composition and uses thereof
US11560421B2 (en) 2018-02-09 2023-01-24 Osaka University Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
JP7644993B2 (ja) 2020-04-17 2025-03-13 ブイエルピー・セラピューティクス・インコーポレイテッド コロナウイルスワクチン
WO2021221127A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
JP2024519195A (ja) * 2021-04-23 2024-05-09 ブイエルピー・セラピューティクス・インコーポレイテッド ガレクチン標的の免疫療法
CN115466330B (zh) * 2021-06-10 2023-10-20 清华大学 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
EP4511479A1 (en) * 2022-04-18 2025-02-26 Cyn-K Bio, Inc. Treatment of inflammatory conditions
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
ATE177755T1 (de) 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
JPH11513249A (ja) 1995-09-27 1999-11-16 メディカル・リサーチ・カウンシル プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
JP2002507393A (ja) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 抗原ライブラリー免疫
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
EP1390398A2 (en) 2001-05-30 2004-02-25 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
AU2003295470A1 (en) 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
CA2527636A1 (en) * 2003-05-29 2005-01-06 United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A Live attenuated viral vaccines for eastern equine encephalitis virus
BRPI0417159A (pt) 2003-12-01 2007-03-06 Dow Global Technologies Inc produção de partìcula semelhante a vìrus icosaédrico recombinante em pseudomÈnades
US20080131461A1 (en) 2004-10-14 2008-06-05 Crucell Holland B.V. Malaria Prime/Boost Vaccines
WO2006088229A1 (ja) 2005-02-16 2006-08-24 The Circle For The Promotion Of Science And Engineering 改変されたウイルスカプシドタンパク質及びその使用
KR101804078B1 (ko) 2005-06-08 2017-12-01 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
JP5627464B2 (ja) 2007-11-26 2014-11-19 ノバルティス アーゲー アルファウイルス粒子を生成する方法
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
PT3067064T (pt) * 2008-12-09 2020-06-16 Novavax Inc Proteínas f vsr modificadas e processos para a sua utilização
US20120219579A1 (en) 2009-09-18 2012-08-30 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
WO2012172574A1 (en) * 2011-06-17 2012-12-20 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
CN104736568A (zh) 2011-10-25 2015-06-24 佛罗里达海湾海岸大学理事会 诱导针对所有登革热病毒血清型的免疫性的疫苗及制造疫苗的方法
BR112014020052B8 (pt) 2012-02-16 2023-04-18 Vlp Therapeutics Llc Partícula do tipo vírus, composições, método de produção de anticorpo e uso da referida partícula
WO2013151764A1 (en) 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
KR20160016856A (ko) 2013-06-03 2016-02-15 브이엘피 테라퓨틱스 엘엘씨 말라리아 백신
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
CN107849558A (zh) 2015-06-12 2018-03-27 国立大学法人三重大学 2型人副流感病毒载体和疫苗
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
CN108601825B (zh) 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Similar Documents

Publication Publication Date Title
JP2017523796A5 (enExample)
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019194236A5 (enExample)
JP2017048194A5 (enExample)
JP2018024670A5 (enExample)
JP2017514877A5 (enExample)
EA201790630A1 (ru) Способы получения рибозидов
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
JP2016525888A5 (enExample)
JP2019524645A5 (enExample)
JP2016153424A5 (enExample)
EP3568155A4 (en) RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
JP2017186358A5 (enExample)
JP2017532302A5 (enExample)
EA201890527A1 (ru) Терапевтические вакцины против hpv18
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
EP3148566C0 (en) LONG SYNTHETIC PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION PURPOSES AGAINST HEPATITIS B VIRUS INFECTION
EP4043031A3 (en) Zika viral antigen constructs
JP2014028813A5 (enExample)
WO2015052543A3 (en) Malaria vaccination
JP2017501211A5 (enExample)
JP2018116258A5 (enExample)
JP2018030858A5 (enExample)